Allen Albright joined MBrace in March 2023 as Senior Vice President Regulatory Affairs. Allen has over 25 years of experience in Regulatory Affairs, including large pharma and biotech industry positions, as well as FDA. Before joining MBrace, Allen was the Vice President of Regulatory Affairs and Quality Assurance at Mirati Therapeutics for almost 9 years where he established and built the department from n=1 to 50 and was instrumental in the clinical development, NDA submission and approval, and commercial launch of KRAZATI for KRAS G12C NSCLC patients, under FDA Fast Track, Breakthrough Therapy, Orphan Drug, and Accelerated Approval designations. Allen has held prior positions of increasing responsibility at Amgen, Baxter, Agensys, Anadys, and Halozyme, having started his regulatory career at the FDA. Allen obtained his BS in Biology from Virginia Tech, and PhD in Microbiology/Immunology from Uniformed Services University of the Health Sciences, and completed post-doctoral research in molecular biology at the Johns Hopkins School of Medicine.